Sector News

Merck & Co. invests $310M, adds 330 jobs to biologics facilities in Ireland

May 30, 2017
Life sciences

Merck & Co., which beefed up its biologics operations in Ireland last year, said it will do so again, investing more than $310 million to expand two sites with plans to add 330 jobs in the process. One of the sites does some of the work on its runaway immuno-oncology success Keytruda.

Merck, known as MSD outside of the U.S. and Canada, announced today that it would invest €280 million over the next three years at its biologics operation in Brinny, County Cork, and also at its vaccines and biologics facilities at Carlow.

The Kenilworth, New Jersey-based company said it will add about 120 or so jobs to its biologics and vaccine site in Carlow. The facility also does some of the work on Keytruda, which has won three FDA approvals this month alone.

The drugmaker also will add more than 200 jobs at its fermentation and sterile filling operation in Cork where it does work on a number of if products including for lung cancer, rheumatoid arthritis and for its hepatitis C program.

“Our existing portfolio and future pipeline ensure current and future employees can operate at the cutting edge of science and technology,” Ger Brennan, managing director of MSD human health in Ireland, said in a statement. “Today, our Irish sites are involved in the production of over 50% of MSD’s global top 20 products…”

Just last year, Merck unveiled plans to add to add 110 jobs at its plant in Carlow and another 50 positions to its operations in Cork.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach